AA
CRL icon

Ancora Advisors’s Charles River Laboratories CRL Stock Holding History

Ancora Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Sell
56
-110
-66% -$19.6K ﹤0.01% 1420
2026
Q1 		$28.6K Buy
166
+12
+8% +$2.23K ﹤0.01% 1376
2025
Q4 		$30.7K Buy
154
+97
+170% +$17.6K ﹤0.01% 1337
2025
Q3 		$8.92K Hold
57
– – ﹤0.01% 1406
2025
Q2 		$8.65K Buy
57
+1
+2% +$133 ﹤0.01% 1402
2025
Q1 		$8.43K Sell
56
-330
-85% -$55.3K ﹤0.01% 1342
2024
Q4 		$71.3K Buy
386
+1
+0.3% +$193 ﹤0.01% 928
2024
Q3 		$75.8K Sell
385
-10,060
-96% -$2.09M ﹤0.01% 892
2024
Q2 		$2.16M Sell
10,445
-6,995
-40% -$1.58M 0.05% 258
2024
Q1 		$4.73M Sell
17,440
-179
-1% -$42.7K 0.11% 169
2023
Q4 		$4.17M Sell
17,619
-696
-4% -$137K 0.1% 179
2023
Q3 		$3.59M Sell
18,315
-6,136
-25% -$1.26M 0.1% 182
2023
Q2 		$5.14M Buy
24,451
+13,885
+131% +$2.76M 0.14% 142
2023
Q1 		$2.13M Sell
10,566
-2,690
-20% -$610K 0.06% 236
2022
Q4 		$2.89M Buy
13,256
+8,100
+157% +$1.77M 0.08% 204
2022
Q3 		$1.01M Buy
5,156
+4,500
+686% +$971K 0.03% 350
2022
Q2 		$140K Sell
656
-70
-10% -$17.1K ﹤0.01% 859
2022
Q1 		$206K Sell
726
-9,779
-93% -$3.02M 0.01% 786
2021
Q4 		$3.96M Sell
10,505
-7,580
-42% -$2.94M 0.09% 191
2021
Q3 		$7.46M Sell
18,085
-2,431
-12% -$1.01M 0.19% 116
2021
Q2 		$7.59M Sell
20,516
-330
-2% -$110K 0.2% 118
2021
Q1 		$6.04M Sell
20,846
-1,710
-8% -$475K 0.17% 137
2020
Q4 		$5.64M Sell
22,556
-230
-1% -$54.8K 0.18% 146
2020
Q3 		$5.16M Sell
22,786
-15,930
-41% -$3.31M 0.2% 119
2020
Q2 		$6.75M Sell
38,716
-23,520
-38% -$3.75M 0.28% 89
2020
Q1 		$7.86M Buy
62,236
+4,140
+7% +$621K 0.36% 75
2019
Q4 		$8.88M Sell
58,096
-14
-0% -$1.94K 0.33% 89
2019
Q3 		$7.69M Buy
58,110
+11,400
+24% +$1.53M 0.34% 93
2019
Q2 		$9.28M Buy
+46,710
New +$6.34M 0.42% 83

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Ancora Advisors's CRL Position: Q2 2026 in Review

Ancora Advisors reduced its Charles River Laboratories (CRL) stake by 66% in Q2 2026, selling an estimated $19.6K and leaving 56 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1420.

Ancora Advisors first reported a position in CRL in Q2 2019 and has held it in 29 quarters since. The position peaked at $9.28M in Q2 2019. 567 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Ancora Advisors held 56 shares of Charles River Laboratories worth $12.7K as of Q2 2026.
  • Ancora Advisors sold 110 Charles River Laboratories shares in Q2 2026, an estimated $19.6K.
  • Charles River Laboratories made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1420 holding.
  • Ancora Advisors first reported a position in Charles River Laboratories in Q2 2019 and has held it in 29 quarters since.
  • Ancora Advisors's Charles River Laboratories position peaked at $9.28M in Q2 2019.
  • 567 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.